FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, today announced that it is a sponsor and exhibitor at BIO 2018, the prestigious annual event that convenes over 16,000 global biotech and pharma leaders from 74 countries. Timed to BIO 2018, Fujifilm also announced the opening of its Cambridge Collaboration Center, located at One Kendall Square in Cambridge, Massachusetts. The facility boasts an atrium with several event and meeting spaces that are designed to facilitate biotech partnership and education.

“With partnering as a key theme of the BIO convention, Fujifilm is thrilled to reveal its new Cambridge Collaboration Center, a space that will encourage partnership between biopharma leaders in Boston and beyond,” said Steve Bagshaw, CEng, FIChemE, Chief Executive Officer of FUJIFILM Diosynth Biotechnologies. “As a center for biotech innovation, at BIO 2018 Fujifilm will showcase its gene therapy manufacturing and development solutions, which are designed to meet the needs of our partners to quickly and reliably support the delivery of advanced therapies to patients.”

At BIO 2018, Fujifilm will sponsor a super session titled, “Delivering on the Promise of Gene Therapy,” scheduled for June 5, 2018 at 2:30PM – 3:45PM in room 253ABC on level 2. Steve Bagshaw, Chief Executive Officer of FUJIFILM Diosynth Biotechnologies will moderate the session that will explore the way gene therapies are transforming patients’ lives in ways that were unimaginable twenty years ago. The session will tackle the challenges and opportunities in gene therapy scientific discovery and new approaches in delivering new types of medicines to patients.

In addition to showcasing its advanced gene therapy manufacturing platform at BIO 2018, Fujifilm will exhibit its full suite of its cGMP CDMO solutions to support partners in development and production.

  •          Saturn™ mAb Platform: As the result of years of experience developing and optimizing monoclonal antibodies processes with efficient cGMP production and batch disposition, the Saturn mAb platform is designed to enable rapid manufacturing capacity, all within a single integrated and efficient workflow.
  •          pAVEway™ Microbial Expression Platform: Innovative and proven technology for the efficient microbial expression of proteins. This platform technology incorporates three key aspects for the delivery of an E.coli based expression process and suitable for large-scale manufacture using antibiotic-free fermentation.
  •          Apollo™ Mammalian Expression Platform: Developed for robust, high levels of recombinant protein expression with manufacturability for the entire product life. With Apollo, Fujifilm delivers a cell line to meet expression needs and regulatory requirements.

To learn more, please visit booth #863 from June 5 – 7, 2018 at BIO 2018 or visit

About Fujifilm

FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract  Development and Manufacturing Organization (CDMO) with locations in Billingham and Redcar, UK, RTP, North Carolina and College Station, Texas.  FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.  For more information, go to:

FUJIFILM Holdings Corporation in Tokyo, Japan, brings innovative solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23.0 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:



All product and company names herein may be trademarks of their registered owners.

Christine Jackman
Manager, Marketing Communications

FUJIFILM Holdings America Corporation
200 Summit Lake Drive
Valhalla, NY 10595
Phone: (914) 789-8523

Back to news